This interaction is separate from the GLP-1 drug
Risks and considerations for microdosing semaglutide Microdosing semaglutide can have the following side effects: Lack of clinical evidence, safety data, and FDA approval Microdosing semaglutide is not recommended by the FDA for weight management or glycemic control
Phase 3: 1.0mg weekly (weeks 9 to 12) Now you are in the therapeutic range
[7] Treatment with Ozempic may lead to reductions in common symptoms associated with PCOS, such as obesity, increased hair growth, menstrual irregularities, and reduced ovarian function
On the lipid side, you don't need a full weight-loss dose to see benefits
It may not be suitable if you have a history of pancreatitis, thyroid cancer, or certain gastrointestinal issues